236 related articles for article (PubMed ID: 19875757)
1. Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy.
Kim DH; Xu W; Kamel-Reid S; Liu X; Jung CW; Kim S; Lipton JH
Ann Oncol; 2010 Jun; 21(6):1179-1188. PubMed ID: 19875757
[TBL] [Abstract][Full Text] [Related]
2. Association of Vascular Endothelial Growth Factor A (VEGFA) and its Receptor (VEGFR2) Gene Polymorphisms with Risk of Chronic Myeloid Leukemia and Influence on Clinical Outcome.
Lakkireddy S; Aula S; Kapley A; Swamy AV; Digumarti RR; Kutala VK; Jamil K
Mol Diagn Ther; 2016 Feb; 20(1):33-44. PubMed ID: 26476544
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of vascular endothelial growth factor type A (VEGFA) and VEGF receptor type 2 (VEGFR2) gene polymorphism in chronic lymphocytic leukemia.
Góra-Tybor J; Szemraj J; Robak T; Jamroziak K
Blood Cells Mol Dis; 2015 Feb; 54(2):139-43. PubMed ID: 25488616
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism can predict the prognosis in acute myeloid leukaemia patients.
Kim DH; Lee NY; Lee MH; Sohn SK; Do YR; Park JY
Br J Haematol; 2008 Jan; 140(1):71-9. PubMed ID: 17983459
[TBL] [Abstract][Full Text] [Related]
5. VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma.
Kim MK; Suh C; Chi HS; Cho HS; Bae YK; Lee KH; Lee GW; Kim IS; Eom HS; Kong SY; Bae SH; Ryoo HM; Shin IH; Mun YC; Chung H; Hyun MS
Cancer Sci; 2012 Mar; 103(3):497-503. PubMed ID: 22129133
[TBL] [Abstract][Full Text] [Related]
6. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
Bedewy AM; El-Maghraby SM
Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
[TBL] [Abstract][Full Text] [Related]
7. Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients.
Elghannam DM; Ibrahim L; Ebrahim MA; Azmy E; Hakem H
Hematology; 2014 Apr; 19(3):123-8. PubMed ID: 23683876
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH
Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153
[TBL] [Abstract][Full Text] [Related]
9. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
10. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
[TBL] [Abstract][Full Text] [Related]
11. Association of Genetic Polymorphisms on VEGFA and VEGFR2 With Risk of Coronary Heart Disease.
Liu D; Song J; Ji X; Liu Z; Cong M; Hu B
Medicine (Baltimore); 2016 May; 95(19):e3413. PubMed ID: 27175642
[TBL] [Abstract][Full Text] [Related]
12. The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia.
Kim DH; Kong JH; Byeun JY; Jung CW; Xu W; Liu X; Kamel-Reid S; Kim YK; Kim HJ; Lipton JH
Clin Cancer Res; 2010 Nov; 16(21):5339-50. PubMed ID: 20959405
[TBL] [Abstract][Full Text] [Related]
13. VEGFR2 and VEGFA polymorphisms are not associated with an inferior prognosis in Caucasian patients with aggressive B-cell lymphoma.
Kaddu-Mulindwa D; Rosolowski M; Ziepert M; Regitz E; Assmann G; Bewarder M; Held G; Pfreundschuh M; Bittenbring JT
Eur J Haematol; 2021 Jan; 106(1):100-104. PubMed ID: 32997825
[TBL] [Abstract][Full Text] [Related]
14. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
[TBL] [Abstract][Full Text] [Related]
15. Relationship between VEGFA polymorphisms and serum VEGF protein levels and recurrent spontaneous miscarriage.
Almawi WY; Saldanha FL; Mahmood NA; Al-Zaman I; Sater MS; Mustafa FE
Hum Reprod; 2013 Oct; 28(10):2628-35. PubMed ID: 23900206
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate].
Zhou KS; Wang YY; Zhao YZ; Yi SH; Qian LS; Wang GR; Yu Z; Wang Y; Wang JX; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):208-12. PubMed ID: 20137149
[TBL] [Abstract][Full Text] [Related]
17. Functional polymorphism of CYP2B6 G15631T is associated with hematologic and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
Kassogue Y; Quachouh M; Dehbi H; Quessar A; Benchekroun S; Nadifi S
Med Oncol; 2014 Jan; 31(1):782. PubMed ID: 24293093
[TBL] [Abstract][Full Text] [Related]
18. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.
Dulucq S; Bouchet S; Turcq B; Lippert E; Etienne G; Reiffers J; Molimard M; Krajinovic M; Mahon FX
Blood; 2008 Sep; 112(5):2024-7. PubMed ID: 18524988
[TBL] [Abstract][Full Text] [Related]
19. OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.
Koren-Michowitz M; Buzaglo Z; Ribakovsky E; Schwarz M; Pessach I; Shimoni A; Beider K; Amariglio N; le Coutre P; Nagler A
Eur J Haematol; 2014 Apr; 92(4):283-8. PubMed ID: 24215657
[TBL] [Abstract][Full Text] [Related]
20. The relation of vascular endothelial growth factor (VEGF) gene polymorphisms on VEGF levels and the risk of vasoocclusive crisis in sickle cell disease.
Al-Habboubi HH; Mahdi N; Abu-Hijleh TM; Abu-Hijleh FM; Sater MS; Almawi WY
Eur J Haematol; 2012 Nov; 89(5):403-9. PubMed ID: 22925497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]